Fresenius Reaches Accord With FTC Over Anemia Drug

Law360, New York (September 15, 2008, 12:00 AM EDT) -- Fresenius Medical Care AG has settled a complaint with the Federal Trade Commission that will allow the company to acquire a license to sell the intravenous iron drug Venofer, but prevents Fresenius from charging more for the drug than current market prices.

The FTC announced both the complaint and the consent decree settling it on Monday. Fresenius had reached an agreement in July with Luitpold Pharmaceuticals Inc., the U.S. subsidiary of the Japanese firm Daiichi Sankyo Co. Ltd., for an exclusive sublicense to manufacture and supply...
To view the full article, register now.